EQ Stock Analysis: Buy, Sell, or Hold?
EQ - Equillium, Inc. Common Stock
$2.26
-0.05 (-2.16%)
âŧ
5d:
-8.87%
30d:
-9.24%
90d:
+0.0%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When EQ Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: EQ is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: EQ is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: EQ is currently trading at $2.26, which is considered fair relative to its 30-day fair value range of $2.16 to $2.52.
Technical Outlook: Technically, EQ is in a strong uptrend. Immediate support is located at $1.96, while resistance sits at $2.55.
Market Sentiment: EQ scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.56 (+270.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EQ is in a strong uptrend. Immediate support is located at $1.96, while resistance sits at $2.55.
Market Sentiment: EQ scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.56 (+270.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.16 -
$2.52
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (32/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 270.4% below Wall St target ($8.56)
- WARNING: Composite score 47/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.16 -
$2.52
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.96
Resistance Level
$2.55
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.86
Wall Street Target
$8.56
(+270.4%)
Revenue Growth (YoY)
-52.3%
Share & Embed Analysis
Last updated: August 24, 2026 10:09 AM ET
Data refreshes hourly during market hours. Next update: 11:09 AM
Data refreshes hourly during market hours. Next update: 11:09 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EQ showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Christine Zedelmayer
SELL
120312 shares
2026-03-13
Christine Zedelmayer
SELL
181219 shares
2026-03-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$370 | 42 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 66 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$313 | 51 HOLD |